1114 related articles for article (PubMed ID: 29079128)
21. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
[TBL] [Abstract][Full Text] [Related]
22. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
[TBL] [Abstract][Full Text] [Related]
23. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.
Wang L; Xu WL; Meng HT; Qian WB; Mai WY; Tong HY; Mao LP; Tong Y; Qian JJ; Lou YJ; Chen ZM; Wang YG; Jin J
J Zhejiang Univ Sci B; 2010 Oct; 11(10):762-70. PubMed ID: 20872983
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
[TBL] [Abstract][Full Text] [Related]
25. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
26. Clinical implications of
Tan M; Ng IKS; Chen Z; Ban K; Ng C; Chiu L; Seah E; Lin M; Tai BC; Yan B; Ng CH; Chng WJ
J Clin Pathol; 2017 Aug; 70(8):669-676. PubMed ID: 28100593
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
28. FLT3 and NPM1 gene mutations in childhood acute myeloblastic leukemia.
Mukda E; Pintaraks K; Sawangpanich R; Wiangnon S; Pakakasama S
Asian Pac J Cancer Prev; 2011; 12(7):1827-31. PubMed ID: 22126574
[TBL] [Abstract][Full Text] [Related]
29. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].
Ruan M; Zhang L; Han C; Liu X; Ai X; Zhang J; Liu T; Yang W; Chen X; Guo Y; Wang S; Li Q; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Apr; 52(4):303-7. PubMed ID: 24915920
[TBL] [Abstract][Full Text] [Related]
30. DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.
Ma J; Dunlap J; Paliga A; Traer E; Press R; Shen L; Fan G
Leuk Lymphoma; 2018 Aug; 59(8):1938-1948. PubMed ID: 29165010
[TBL] [Abstract][Full Text] [Related]
31. Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2019 Jun; 20(6):1749-1755. PubMed ID: 31244296
[TBL] [Abstract][Full Text] [Related]
32. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
[TBL] [Abstract][Full Text] [Related]
33. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
Guryanova OA; Shank K; Spitzer B; Luciani L; Koche RP; Garrett-Bakelman FE; Ganzel C; Durham BH; Mohanty A; Hoermann G; Rivera SA; Chramiec AG; Pronier E; Bastian L; Keller MD; Tovbin D; Loizou E; Weinstein AR; Gonzalez AR; Lieu YK; Rowe JM; Pastore F; McKenney AS; Krivtsov AV; Sperr WR; Cross JR; Mason CE; Tallman MS; Arcila ME; Abdel-Wahab O; Armstrong SA; Kubicek S; Staber PB; Gönen M; Paietta EM; Melnick AM; Nimer SD; Mukherjee S; Levine RL
Nat Med; 2016 Dec; 22(12):1488-1495. PubMed ID: 27841873
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population.
Suzuki R; Onizuka M; Kojima M; Shimada M; Okamura K; Fukagawa S; Tsuboi K; Kikuchi A; Kobayashi H; Shintani A; Ogawa Y; Kawada H; Hotta T; Ando K
Int J Hematol; 2007 Dec; 86(5):422-8. PubMed ID: 18192111
[TBL] [Abstract][Full Text] [Related]
35. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
Gaidzik VI; Schlenk RF; Paschka P; Stölzle A; Späth D; Kuendgen A; von Lilienfeld-Toal M; Brugger W; Derigs HG; Kremers S; Greil R; Raghavachar A; Ringhoffer M; Salih HR; Wattad M; Kirchen HG; Runde V; Heil G; Petzer AL; Girschikofsky M; Heuser M; Kayser S; Goehring G; Teleanu MV; Schlegelberger B; Ganser A; Krauter J; Bullinger L; Döhner H; Döhner K
Blood; 2013 Jun; 121(23):4769-77. PubMed ID: 23632886
[TBL] [Abstract][Full Text] [Related]
36. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
38. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
[TBL] [Abstract][Full Text] [Related]
39. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
[TBL] [Abstract][Full Text] [Related]
40. Fms like tyrosine kinase (FLT3) and nucleophosmin 1 (NPM1) mutations in de novo normal karyotype acute myeloid leukemia (AML).
Dunna NR; Rajappa S; Digumarti R; Vure S; Kagita S; Damineni S; Rao VR; Yadav SK; Ravuri RR; Satti V
Asian Pac J Cancer Prev; 2010; 11(6):1811-6. PubMed ID: 21338238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]